- Home
- MYNZ vs OGEN Comparison
MYNZ vs OGEN Comparison
Compare MYNZ & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYNZ | OGEN |
|---|---|---|
| Founded | 2021 | 1996 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 3.6M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | MYNZ | OGEN |
|---|---|---|
| Price | $1.24 | $0.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $14.00 | N/A |
| AVG Volume (30 Days) | ★ 188.9K | 82.3K |
| Earning Date | 12-29-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $659,935.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.82 |
| 52 Week High | $8.20 | $18.90 |
Technical Indicators
Market Signals| Indicator | MYNZ | OGEN |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 41.15 |
| Support Level | $1.00 | $0.85 |
| Resistance Level | $1.15 | $0.99 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 76.27 | 27.52 |
Price Performance
Historical ComparisonAbout MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.